STERIS plc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that STERIS plc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $5.46B | May 29, 2025 |
| FY2024 | Mar 31, 2024 | $1.42B | May 29, 2024 |
| FY2024 | Dec 31, 2023 | $1.30B | May 29, 2024 |
| FY2024 | Sep 30, 2023 | $1.24B | May 29, 2024 |
| FY2024 | Jun 30, 2023 | $1.18B | May 29, 2024 |
| FY2024 | Mar 31, 2023 | $1.28B | May 29, 2024 |
| FY2024 | Dec 31, 2022 | $1.11B | May 29, 2024 |
| FY2024 | Sep 30, 2022 | $1.09B | May 29, 2024 |
| FY2024 | Jun 30, 2022 | $1.05B | May 29, 2024 |
| FY2022 | Mar 31, 2022 | $1.21B | May 31, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $2.40B | May 29, 2025 |
| FY2024 | Mar 31, 2024 | $582.90M | May 29, 2024 |
| FY2024 | Dec 31, 2023 | $560.03M | May 29, 2024 |
| FY2024 | Sep 30, 2023 | $546.23M | May 29, 2024 |
| FY2024 | Jun 30, 2023 | $529.00M | May 29, 2024 |
| FY2024 | Mar 31, 2023 | $546.40M | May 29, 2024 |
| FY2024 | Dec 31, 2022 | $478.19M | May 29, 2024 |
| FY2024 | Sep 30, 2022 | $482.31M | May 29, 2024 |
| FY2024 | Jun 30, 2022 | $473.83M | May 29, 2024 |
| FY2022 | Mar 31, 2022 | $571.62M | May 31, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $614.64M | May 29, 2025 |
| FY2024 | Mar 31, 2024 | ($1.38M) | May 29, 2024 |
| FY2024 | Dec 31, 2023 | $140.74M | May 29, 2024 |
| FY2024 | Sep 30, 2023 | $115.32M | May 29, 2024 |
| FY2024 | Jun 30, 2023 | $123.55M | May 29, 2024 |
| FY2024 | Mar 31, 2023 | $187.23M | May 29, 2024 |
| FY2024 | Dec 31, 2022 | $123.83M | May 29, 2024 |
| FY2024 | Sep 30, 2022 | ($315.29M) | May 29, 2024 |
| FY2024 | Jun 30, 2022 | $111.26M | May 29, 2024 |
| FY2022 | Mar 31, 2022 | $52.26M | May 31, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $866.64M | May 29, 2025 |
| FY2025 | Mar 31, 2024 | $836.12M | May 29, 2025 |
| FY2025 | Mar 31, 2023 | $791.10M | May 29, 2025 |
| FY2024 | Mar 31, 2022 | $477.82M | May 29, 2024 |
| FY2023 | Mar 31, 2021 | $548.37M | May 26, 2023 |
| FY2022 | Mar 31, 2020 | $537.05M | May 31, 2022 |
| FY2021 | Mar 31, 2019 | $411.02M | May 28, 2021 |
| FY2020 | Mar 31, 2018 | $399.88M | May 29, 2020 |
| FY2019 | Mar 31, 2017 | $226.21M | May 30, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $107.65M | May 29, 2025 |
| FY2025 | Mar 31, 2024 | $103.68M | May 29, 2025 |
| FY2025 | Mar 31, 2023 | $98.48M | May 29, 2025 |
| FY2024 | Mar 31, 2022 | $86.66M | May 29, 2024 |
| FY2023 | Mar 31, 2021 | $66.33M | May 26, 2023 |
| FY2022 | Mar 31, 2020 | $65.55M | May 31, 2022 |
| FY2021 | Mar 31, 2019 | $63.04M | May 28, 2021 |
| FY2020 | Mar 31, 2018 | $60.78M | May 29, 2020 |
| FY2019 | Mar 31, 2017 | $59.40M | May 30, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $1.33B | May 29, 2025 |
| FY2025 | Mar 31, 2024 | $1.25B | May 29, 2025 |
| FY2025 | Mar 31, 2023 | $1.09B | May 29, 2025 |
| FY2024 | Mar 31, 2022 | $1.32B | May 29, 2024 |
| FY2023 | Mar 31, 2021 | $731.32M | May 26, 2023 |
| FY2022 | Mar 31, 2020 | $716.73M | May 31, 2022 |
| FY2021 | Mar 31, 2019 | $669.94M | May 28, 2021 |
| FY2020 | Mar 31, 2018 | $631.98M | May 29, 2020 |
| FY2019 | Mar 31, 2017 | $682.04M | May 30, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $1.15B | May 29, 2025 |
| FY2025 | Mar 31, 2024 | $973.27M | May 29, 2025 |
| FY2025 | Mar 31, 2023 | $756.95M | May 29, 2025 |
| FY2024 | Mar 31, 2022 | $684.81M | May 29, 2024 |
| FY2023 | Mar 31, 2021 | $689.64M | May 26, 2023 |
| FY2022 | Mar 31, 2020 | $590.56M | May 31, 2022 |
| FY2021 | Mar 31, 2019 | $539.51M | May 28, 2021 |
| FY2020 | Mar 31, 2018 | $457.63M | May 29, 2020 |
| FY2019 | Mar 31, 2017 | $424.09M | May 30, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $370.09M | May 29, 2025 |
| FY2025 | Mar 31, 2024 | $360.33M | May 29, 2025 |
| FY2025 | Mar 31, 2023 | $361.97M | May 29, 2025 |
| FY2024 | Mar 31, 2022 | $287.56M | May 29, 2024 |
| FY2023 | Mar 31, 2021 | $239.26M | May 26, 2023 |
| FY2022 | Mar 31, 2020 | $214.52M | May 31, 2022 |
| FY2021 | Mar 31, 2019 | $189.72M | May 28, 2021 |
| FY2020 | Mar 31, 2018 | $165.46M | May 29, 2020 |
| FY2019 | Mar 31, 2017 | $172.90M | May 30, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $10.15B | May 29, 2025 |
| FY2025 | Mar 31, 2024 | $11.06B | May 29, 2025 |
| FY2024 | Mar 31, 2023 | $10.82B | May 29, 2024 |
| FY2023 | Mar 31, 2022 | $11.42B | May 26, 2023 |
| FY2022 | Mar 31, 2021 | $6.57B | May 31, 2022 |
| FY2021 | Mar 31, 2020 | $5.44B | May 28, 2021 |
| FY2020 | Mar 31, 2019 | $5.07B | May 29, 2020 |
| FY2019 | Mar 31, 2018 | $5.20B | May 30, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $3.53B | May 29, 2025 |
| FY2025 | Mar 31, 2024 | $4.75B | May 29, 2025 |
| FY2024 | Mar 31, 2023 | $4.73B | May 29, 2024 |
| FY2023 | Mar 31, 2022 | $4.88B | May 26, 2023 |
| FY2022 | Mar 31, 2021 | $2.68B | May 31, 2022 |
| FY2021 | Mar 31, 2020 | $2.02B | May 28, 2021 |
| FY2020 | Mar 31, 2019 | $1.89B | May 29, 2020 |
| FY2019 | Mar 31, 2018 | $1.98B | May 30, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $6.60B | May 29, 2025 |
| FY2025 | Mar 31, 2024 | $6.30B | May 29, 2025 |
| FY2024 | Mar 31, 2023 | $6.08B | May 29, 2024 |
| FY2023 | Mar 31, 2022 | $6.53B | May 26, 2023 |
| FY2022 | Mar 31, 2021 | $3.88B | May 31, 2022 |
| FY2021 | Mar 31, 2020 | $3.41B | May 28, 2021 |
| FY2020 | Mar 31, 2019 | $3.18B | May 29, 2020 |
| FY2019 | Mar 31, 2018 | $3.21B | May 30, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $4.10B | May 29, 2025 |
| FY2025 | Mar 31, 2024 | $4.07B | May 29, 2025 |
| FY2025 | Mar 31, 2023 | $3.88B | May 29, 2025 |
| FY2024 | Mar 31, 2022 | $3.94B | May 29, 2024 |
| FY2023 | Mar 31, 2021 | $3.03B | May 26, 2023 |
| FY2022 | Mar 31, 2020 | $2.36B | May 31, 2022 |
| FY2021 | Mar 31, 2019 | $2.32B | May 28, 2021 |
| FY2020 | Mar 31, 2018 | $2.43B | May 29, 2020 |
| FY2019 | Mar 31, 2017 | $2.23B | May 30, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $2.48B | May 29, 2025 |
| FY2025 | Mar 31, 2024 | $2.09B | May 29, 2025 |
| FY2024 | Mar 31, 2023 | $1.91B | May 29, 2024 |
| FY2023 | Mar 31, 2022 | $2.00B | May 26, 2023 |
| FY2022 | Mar 31, 2021 | $1.94B | May 31, 2022 |
| FY2021 | Mar 31, 2020 | $1.66B | May 28, 2021 |
| FY2020 | Mar 31, 2019 | $1.34B | May 29, 2020 |
| FY2019 | Mar 31, 2018 | $1.15B | May 30, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Mar 31, 2021 | $220.53M | May 28, 2021 |
| FY2021 | Mar 31, 2020 | $319.58M | May 28, 2021 |
| FY2021 | Mar 31, 2019 | $220.63M | May 28, 2021 |
| FY2021 | Mar 31, 2018 | $201.53M | May 28, 2021 |
| FY2020 | Mar 31, 2017 | $282.92M | May 29, 2020 |
| FY2019 | Mar 31, 2016 | $248.84M | May 30, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $1.92B | May 29, 2025 |
| FY2025 | Mar 31, 2024 | $3.12B | May 29, 2025 |
| FY2024 | Mar 31, 2023 | $3.02B | May 29, 2024 |
| FY2023 | Mar 31, 2022 | $2.95B | May 26, 2023 |
| FY2022 | Mar 31, 2021 | $1.65B | May 31, 2022 |
| FY2021 | Mar 31, 2020 | $1.15B | May 28, 2021 |
| FY2020 | Mar 31, 2019 | $1.18B | May 29, 2020 |
| FY2019 | Mar 31, 2018 | $1.32B | May 30, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 6 | May 29, 2025 |
| FY2024 | Mar 31, 2024 | 0 | May 29, 2024 |
| FY2024 | Dec 31, 2023 | 1 | May 29, 2024 |
| FY2024 | Sep 30, 2023 | 1 | May 29, 2024 |
| FY2024 | Jun 30, 2023 | 1 | May 29, 2024 |
| FY2024 | Mar 31, 2023 | 1 | May 29, 2024 |
| FY2024 | Dec 31, 2022 | 1 | May 29, 2024 |
| FY2024 | Sep 30, 2022 | (3) | May 29, 2024 |
| FY2024 | Jun 30, 2022 | 1 | May 29, 2024 |
| FY2022 | Mar 31, 2022 | 0 | May 31, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 6 | May 29, 2025 |
| FY2024 | Mar 31, 2024 | 0 | May 29, 2024 |
| FY2024 | Dec 31, 2023 | 1 | May 29, 2024 |
| FY2024 | Sep 30, 2023 | 1 | May 29, 2024 |
| FY2024 | Jun 30, 2023 | 1 | May 29, 2024 |
| FY2024 | Mar 31, 2023 | 1 | May 29, 2024 |
| FY2024 | Dec 31, 2022 | 1 | May 29, 2024 |
| FY2024 | Sep 30, 2022 | (3) | May 29, 2024 |
| FY2024 | Jun 30, 2022 | 1 | May 29, 2024 |
| FY2022 | Mar 31, 2022 | 0 | May 31, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 98.30M | May 29, 2025 |
| FY2025 | Mar 31, 2024 | 98.88M | May 29, 2025 |
| FY2024 | Mar 31, 2023 | 98.63M | May 29, 2024 |
| FY2023 | Mar 31, 2022 | 100.07M | May 26, 2023 |
| FY2022 | Mar 31, 2021 | 85.35M | May 31, 2022 |
| FY2021 | Mar 31, 2020 | 84.92M | May 28, 2021 |
| FY2020 | Mar 31, 2019 | 84.52M | May 29, 2020 |
| FY2019 | Mar 31, 2018 | 84.75M | May 30, 2019 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $219.88M | May 29, 2025 |
| FY2025 | Mar 31, 2024 | $200.57M | May 29, 2025 |
| FY2025 | Mar 31, 2023 | $183.50M | May 29, 2025 |
| FY2024 | Mar 31, 2022 | $163.17M | May 29, 2024 |
| FY2023 | Mar 31, 2021 | $133.84M | May 26, 2023 |
| FY2022 | Mar 31, 2020 | $123.03M | May 31, 2022 |
| FY2021 | Mar 31, 2019 | $112.50M | May 28, 2021 |
| FY2020 | Mar 31, 2018 | $102.93M | May 29, 2020 |
| FY2019 | Mar 31, 2017 | $93.19M | May 30, 2019 |